Pamela Bush, PhD, of Predictive Oncology talks about the company’s technology to use artificial intelligence (AI) to develop cancer medications. 

As Dr. Bush notes, a proof of concept study demonstrated that the company’s  PeDAL platform can predict a tumor’s response to a drug with 92% accuracy. PeDAL platform features a unique combination of AI technology, drug response data and a biobank of over 150,000 tumor samples for 137 tumor types. 

Traditionally, potential drugs are tested against cell lines, tissue samples, etc for efficacy.  This is costly and time prohibitive. By combining AI-driven predictions with a a biobank of 150,000 tumor samples, PeDAL improves the probability of finding a potential oncology drug that can enter into clinical development.  To learn more about this platform, visit 

To stay abreast of the latest developments in oncology, sign up to our newsletter at